Document is current
Any future updates will be listed below
-
Authors
Winstanley, Yasmyn E. https://orcid.org/0000-0002-0196-0965
Rose, Ryan D. https://orcid.org/0000-0001-9732-1713
Sobinoff, Alexander P. https://orcid.org/0000-0001-6679-5211
Wu, Linda L.
Adhikari, Deepak https://orcid.org/0000-0002-3404-8753
Zhang, Qing-Hua
Wells, Jadon K. https://orcid.org/0009-0007-4809-827X
Wong, Lee H. https://orcid.org/0000-0002-4005-7330
Szeto, Hazel H. https://orcid.org/0000-0003-4021-5076
Piltz, Sandra G. https://orcid.org/0000-0003-3386-8140
Thomas, Paul Q. https://orcid.org/0000-0002-5002-5770
Febbraio, Mark A. https://orcid.org/0000-0002-9296-4418
Carroll, John https://orcid.org/0000-0001-9644-5861
Pickett, Hilda A. https://orcid.org/0000-0002-9840-4841
Russell, Darryl L. https://orcid.org/0000-0002-4930-7658
Robker, Rebecca L. https://orcid.org/0000-0002-1538-4604
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1130364, APP1117975, APP1194141)
Channel 7 Children's Research Foundation (20669397)
- License Information
-
More Information
Article History
Received: 15 June 2023
Accepted: 2 March 2025
First Online: 14 March 2025
Competing interests
: Y.E.W. and R.L.R. are inventors on a patent application (PCT/US23/69908) related to this work. R.L.R. is a consultant with Mitochon Technologies and Vitaleon Pharma. M.A.F. is a shareholder and consultant with N-Gene Research Laboratories Inc and is founder and shareholder of Celesta Therapeutics. H.H.S. is the inventor of SS-31 (USPTO 7,576,601; August 18, 2009). The remaining authors declare no competing interests.
